HOLX
Hologic, Inc.
Medical - Instruments & Supplies
Market Cap$16.97B
5Y Perf.+43.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
HOLX vs TMO
Revenue, margins, valuation, and 5-year total return — side by side.
TMO
Thermo Fisher Scientific Inc.
Medical - Diagnostics & Research
Market Cap$175.76B
5Y Perf.+40.8%
HOLX vs TMO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | HOLX | TMO |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Diagnostics & Research |
| Market Cap | $16.97B | $175.76B |
| Revenue (TTM) | $4.13B | $45.20B |
| Net Income (TTM) | $544M | $6.86B |
| Gross Margin | 52.8% | 39.4% |
| Operating Margin | 17.5% | 17.8% |
| Forward P/E | 17.2x | 19.0x |
| Total Debt | $2.63B | $40.85B |
| Cash & Equiv. | $1.96B | $9.86B |
HOLX vs TMO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
HOLX
TMO
| Stock | May 20 | Apr 26 | Return |
|---|---|---|---|
| Hologic, Inc. (HOLX) | 100 | 143.4 | +43.4% |
| Thermo Fisher Scien… (TMO) | 100 | 140.8 | +40.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HOLX vs TMO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TMO leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Hologic, Inc. is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
HOLX
Hologic, Inc.
The Income Pick
HOLX is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.41
- Lower volatility, beta 0.41, Low D/E 52.0%, current ratio 3.75x
- Beta 0.41, current ratio 3.75x
Best for: income & stability and sleep-well-at-night
TMO
Thermo Fisher Scientific Inc.
The Growth Play
TMO carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 3.9%, EPS growth 7.3%, 3Y rev CAGR -0.3%
- 229.1% 10Y total return vs HOLX's 125.4%
- 3.9% revenue growth vs HOLX's 1.7%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TMO | 3.9% revenue growth vs HOLX's 1.7% |
| Value | HOLX | Lower P/E (17.2x vs 19.0x) |
| Quality / Margins | TMO | 15.2% margin vs HOLX's 13.2% |
| Stability / Safety | HOLX | Beta 0.41 vs TMO's 1.10, lower leverage |
| Dividends | TMO | 0.4% yield; 8-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | HOLX | +43.1% vs TMO's +16.6% |
| Efficiency (ROA) | TMO | 6.4% ROA vs HOLX's 5.9%, ROIC 7.5% vs 9.4% |
HOLX vs TMO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
HOLX vs TMO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLHOLXLAGGINGTMO
TMOThermo Fisher Scienti…
1leads
HOLXHologic, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs TMOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TMO4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
HOLX6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
HOLX5/6
Risk & VolatilityBeta, volatility, and downside exposure
HOLX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
TMO leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 11.0x HOLX's $4.1B. Profitability is closely matched — net margins range from 15.2% (TMO) to 13.2% (HOLX). On growth, TMO holds the edge at +6.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | HOLXHologic, Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| RevenueTrailing 12 months | $4.1B | $45.2B |
| EBITDAEarnings before interest/tax | $974M | $10.5B |
| Net IncomeAfter-tax profit | $544M | $6.9B |
| Free Cash FlowCash after capex | $1000M | $6.7B |
| Gross MarginGross profit ÷ Revenue | +52.8% | +39.4% |
| Operating MarginEBIT ÷ Revenue | +17.5% | +17.8% |
| Net MarginNet income ÷ Revenue | +13.2% | +15.2% |
| FCF MarginFCF ÷ Revenue | +24.2% | +14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.5% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -9.2% | +11.3% |
TMO leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — HOLX and TMO each lead in 3 of 6 comparable metrics.
Valuation Metrics
At 26.7x trailing earnings, TMO trades at a 13% valuation discount to HOLX's 30.5x P/E. On an enterprise value basis, HOLX's 17.4x EV/EBITDA is more attractive than TMO's 19.0x.
| Metric | HOLXHologic, Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| Market CapShares × price | $17.0B | $175.8B |
| Enterprise ValueMkt cap + debt − cash | $17.6B | $206.8B |
| Trailing P/EPrice ÷ TTM EPS | 30.53x | 26.66x |
| Forward P/EPrice ÷ next-FY EPS est. | 17.21x | 19.04x |
| PEG RatioP/E ÷ EPS growth rate | — | 12.62x |
| EV / EBITDAEnterprise value multiple | 17.39x | 18.99x |
| Price / SalesMarket cap ÷ Revenue | 4.14x | 3.94x |
| Price / BookPrice ÷ Book value/share | 3.43x | 3.33x |
| Price / FCFMarket cap ÷ FCF | 18.44x | 27.93x |
Evenly matched — HOLX and TMO each lead in 3 of 6 comparable metrics.
Profitability & Efficiency
HOLX leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
TMO delivers a 13.2% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $10 for HOLX. HOLX carries lower financial leverage with a 0.52x debt-to-equity ratio, signaling a more conservative balance sheet compared to TMO's 0.76x. On the Piotroski fundamental quality scale (0–9), HOLX scores 7/9 vs TMO's 6/9, reflecting strong financial health.
| Metric | HOLXHologic, Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| ROE (TTM)Return on equity | +10.4% | +13.2% |
| ROA (TTM)Return on assets | +5.9% | +6.4% |
| ROICReturn on invested capital | +9.4% | +7.5% |
| ROCEReturn on capital employed | +8.8% | +9.1% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.52x | 0.76x |
| Net DebtTotal debt minus cash | $667M | $31.0B |
| Cash & Equiv.Liquid assets | $2.0B | $9.9B |
| Total DebtShort + long-term debt | $2.6B | $40.9B |
| Interest CoverageEBIT ÷ Interest expense | 8.00x | 5.89x |
HOLX leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
HOLX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HOLX five years ago would be worth $11,665 today (with dividends reinvested), compared to $10,211 for TMO. Over the past 12 months, HOLX leads with a +43.1% total return vs TMO's +16.6%. The 3-year compound annual growth rate (CAGR) favors HOLX at -2.9% vs TMO's -4.2% — a key indicator of consistent wealth creation.
| Metric | HOLXHologic, Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| YTD ReturnYear-to-date | +1.9% | -20.1% |
| 1-Year ReturnPast 12 months | +43.1% | +16.6% |
| 3-Year ReturnCumulative with dividends | -8.5% | -11.9% |
| 5-Year ReturnCumulative with dividends | +16.7% | +2.1% |
| 10-Year ReturnCumulative with dividends | +125.4% | +229.1% |
| CAGR (3Y)Annualised 3-year return | -2.9% | -4.2% |
HOLX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
HOLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than TMO's 1.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs TMO's 73.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | HOLXHologic, Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.41x | 1.10x |
| 52-Week HighHighest price in past year | $76.04 | $643.99 |
| 52-Week LowLowest price in past year | $51.90 | $385.46 |
| % of 52W HighCurrent price vs 52-week peak | +100.0% | +73.4% |
| RSI (14)Momentum oscillator 0–100 | 69.1 | 39.8 |
| Avg Volume (50D)Average daily shares traded | 9.7M | 1.9M |
HOLX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates HOLX as "Hold" and TMO as "Buy". Consensus price targets imply 38.4% upside for TMO (target: $655) vs 3.9% for HOLX (target: $79). TMO is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.
| Metric | HOLXHologic, Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $79.00 | $654.67 |
| # AnalystsCovering analysts | 42 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 8 |
| Dividend / ShareAnnual DPS | — | $1.69 |
| Buyback YieldShare repurchases ÷ mkt cap | +4.4% | +1.7% |
Insufficient data to determine a leader in this category.
Key Takeaway
HOLX leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). TMO leads in 1 (Income & Cash Flow). 1 tied.
Best OverallHologic, Inc. (HOLX)Leads 3 of 6 categories
Loading custom metrics...
HOLX vs TMO: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is HOLX or TMO a better buy right now?
For growth investors, Thermo Fisher Scientific Inc.
(TMO) is the stronger pick with 3. 9% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 7x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate Thermo Fisher Scientific Inc. (TMO) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — HOLX or TMO?
On trailing P/E, Thermo Fisher Scientific Inc.
(TMO) is the cheapest at 26. 7x versus Hologic, Inc. at 30. 5x. On forward P/E, Hologic, Inc. is actually cheaper at 17. 2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — HOLX or TMO?
Over the past 5 years, Hologic, Inc.
(HOLX) delivered a total return of +16. 7%, compared to +2. 1% for Thermo Fisher Scientific Inc. (TMO). Over 10 years, the gap is even starker: TMO returned +229. 1% versus HOLX's +125. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — HOLX or TMO?
By beta (market sensitivity over 5 years), Hologic, Inc.
(HOLX) is the lower-risk stock at 0. 41β versus Thermo Fisher Scientific Inc. 's 1. 10β — meaning TMO is approximately 167% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Hologic, Inc. (HOLX) carries a lower debt/equity ratio of 52% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — HOLX or TMO?
By revenue growth (latest reported year), Thermo Fisher Scientific Inc.
(TMO) is pulling ahead at 3. 9% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: Thermo Fisher Scientific Inc. grew EPS 7. 3% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, TMO leads at -0. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — HOLX or TMO?
Thermo Fisher Scientific Inc.
(TMO) is the more profitable company, earning 15. 1% net margin versus 13. 8% for Hologic, Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus 17. 4% for HOLX. At the gross margin level — before operating expenses — HOLX leads at 61. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is HOLX or TMO more undervalued right now?
On forward earnings alone, Hologic, Inc.
(HOLX) trades at 17. 2x forward P/E versus 19. 0x for Thermo Fisher Scientific Inc. — 1. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMO: 38. 4% to $654. 67.
08Which pays a better dividend — HOLX or TMO?
In this comparison, TMO (0.
4% yield) pays a dividend. HOLX does not pay a meaningful dividend and should not be held primarily for income.
09Is HOLX or TMO better for a retirement portfolio?
For long-horizon retirement investors, Hologic, Inc.
(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +125. 4% 10Y return). Both have compounded well over 10 years (HOLX: +125. 4%, TMO: +229. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between HOLX and TMO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(HOLX: 2.5% · TMO: 6.2%)Net Margin>
%
(HOLX: 13.2% · TMO: 15.2%)P/E Ratio<
x
(HOLX: 30.5x · TMO: 26.7x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.